Alnylam Pharmaceuticals, Inc. in 2 stories
The narratives ALNY currently appears in, with its side and exposure in each.
Bull side
1 story- The Patent Cliff Sparks a Biotech Land Grab
ALNY in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Alnylam's validated RNA-interference platform and growing commercial portfolio make its pipeline strategically scarce.
Bear side
1 story- America Imports the World's Drug Prices
ALNY in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Alnylam's high-priced RNA-interference medicines rely on orphan-drug economics that could be diluted if US payers import lower overseas benchmarks.